NasdaqGS:KNSABiotechs
Does Raised 2026 Revenue Guidance Change The Bull Case For Kiniksa Pharmaceuticals International (KNSA)?
Kiniksa Pharmaceuticals International, plc recently reported its second-quarter 2026 results, with revenue of US$243.6 million and net income of US$25.43 million, and raised its full-year 2026 net product revenue guidance to a range of US$980 million to US$995 million from US$930 million to US$945 million.
The combination of higher guidance and year-on-year growth in revenue and earnings per share highlights management’s increased confidence in the durability of the company’s current...